EXEL

EXEL

USD

Exelixis Inc. Common Stock

$37.900+0.090 (0.238%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$37.810

最高价

$38.900

最低价

$37.582

成交量

2.81M

公司基本面

市值

10.2B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

2.62M

交易所

NMS

货币

USD

52周价格范围

最低价 $31.9当前价 $37.900最高价 $49.62

相关新闻

BusinessWire

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for

查看更多
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Analyst Upgrades

Guggenheim Downgrades Exelixis to Neutral

Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.

查看更多
Guggenheim Downgrades Exelixis to Neutral
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...

查看更多
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
BusinessWire

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after

查看更多
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44

Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.

查看更多
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Analyst Upgrades

RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target

RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30

Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.